PEPTIDEREPORT

FDA · Enforcement

D&H Medical Services: FDA Warning Letter 728238

FDA issued a warning letter concerning website presentation and marketing claims for compounded semaglutide and tirzepatide products. The linked source is the agency's complete public record.

Agency warning legal stageJun 8, 2026 record dateUnited States jurisdiction
Open the primary-source record

Record status

Open public record

Agency
U.S. Food and Drug Administration
Action
Warning letter
Stage
Agency warning
Last verified
Jul 10, 2026

Source-backed timeline

Status history

  1. Warning letter issuedSource

Editorial boundary: Peptide Report summarizes the public source and preserves its procedural stage. This page does not convert an allegation, proposal, advisory discussion, or warning into a final legal conclusion.

Back to all Regulatory Watch records